Mizuho's New Price Target#
Mizuho has raised its price target for Axsome Therapeutics stock (NASDAQ:AXSM) from $228 to $310 while keeping an Outperform rating. This adjustment reflects the firm’s confidence in the company’s flagship drug, Auvelity, and its potential in the market.
Increased Revenue Estimates#
The firm has significantly increased its revenue estimate for Auvelity, projecting peak sales of $5.0 billion by 2038, up from a previous estimate of $3.2 billion. This optimism is supported by Axsome's recent performance, which saw a revenue increase of 66% year-over-year, totaling $638.5 million, with a high gross profit margin of 92.6%.
Positive Market Outlook#
The revised outlook indicates strong confidence in Auvelity’s performance in treating depression after 3.5 years on the market. Additionally, Axsome has expanded its sales team to over 600 representatives, which could enhance its market reach. The company has updated its peak revenue guidance for Auvelity to at least $8 billion, a significant increase from the earlier range of $2.5 billion to $6.0 billion.
Analyst Reactions#
The new price target of $310 suggests about a 40% upside potential compared to a consensus target of $256. Other analysts have also raised their price targets for Axsome following the company’s strong earnings report. For instance, B.Riley set a target of $300, while RBC Capital adjusted theirs to $302, citing improved revenue outlooks. Oppenheimer and Guggenheim have also increased their targets, reflecting the positive market sentiment surrounding Auvelity and Axsome’s strategic initiatives.